[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635401":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":20,"responsibleParty":27,"collaborators":20,"id":29,"slug":20,"hasResults":30,"nctId":31,"briefTitle":32,"officialTitle":33,"acronym":34,"eligibilityCriteria":35,"healthyVolunteers":30,"sex":36,"minAge":37,"maxAge":38,"enrollmentInfo":39,"targetDuration":20,"studyType":42,"phases":43,"briefSummary":45,"conditions":46,"keywords":50,"overallStatus":56,"whyStopped":20,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":20},{"fullName":5,"class":6},"Peking University Cancer Hospital & Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Rectal Cancer Patients","EXPERIMENTAL","Patients with confirmed middle to high rectal adenocarcinoma who are scheduled for radical surgery.",[13],"Diagnostic Test: PET\u002FMRI with 18F-FDG and [68Ga]Ga-CTR-FAPI",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","PET\u002FMRI with 18F-FDG and [68Ga]Ga-CTR-FAPI","Diagnostic Test: 18F-FDG PET\u002FMRI\n\nDescription: Patients receive an intravenous injection of 18F-FDG (3.7-5.5 MBq\u002Fkg).\n\nDiagnostic Test: \\[68Ga\\]Ga-CTR-FAPI PET\u002FMRI\n\nDescription: Patients receive an intravenous injection of \\[68Ga\\]Ga-CTR-FAPI (1.8-3.7 MBq\u002Fkg).",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Minghe Zhao","CONTACT","0086-15600896700","dzhao3163@gmail.com",{"type":28,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100635401",false,"NCT07552207","Comparison of [68Ga]Ga-CTR-FAPI and 18F-FDG PET\u002FMRI for Lymph Node Staging in Rectal Cancer","Comparison of the Diagnostic Efficacy of [68Ga]Ga-CTR-FAPI PET\u002FMRI and 18F-FDG PET\u002FMRI for Lymph Node Metastasis in Middle to High Rectal Cancer","PKUCH-R12","Inclusion Criteria:\n\n* Confirmed rectal adenocarcinoma by pathological biopsy.\n* Lower margin of the tumor is ≥ 5 cm and ≤15 cm from the anal verge.\n* Planned to undergo radical surgery.\n* ECOG performance status score ≤ 2.\n* Patient is willing to undergo PET\u002FMRI examination.\n\nExclusion Criteria:\n\n* History of pelvic radiotherapy or chemotherapy.\n* Concurrent with other malignant tumors or active infections.\n* Pregnant or unable to sign the informed consent form.\n* Claustrophobia or inability to tolerate MRI examinations due to other reasons.","ALL","18 Years","75 Years",{"count":40,"type":41},30,"ESTIMATED","INTERVENTIONAL",[44],"NA","This is a prospective, single-center, diagnostic study designed to compare the accuracy of \\[68Ga\\]Ga-CTR-FAPI PET\u002FMRI and \\[18\\]F-FDG PET\u002FMRI for the detection of lymph node metastasis in patients with initially untreated, resectable middle to high rectal cancer. The study aims to evaluate whether \\[68Ga\\]Ga-CTR-FAPI PET\u002FMRI provides higher sensitivity and specificity than traditional 18F-FDG PET\u002FMRI at both the patient level and the lymph node level.",[47,48,49],"Rectal Cancer","Lymph Node Metastases","PET \u002F MR",[51,52,53,54,55],"PET\u002FMR","[68Ga]Ga-CTR-FAPI","18F-FDG","Lymph Node Staging","Radiomics","NOT_YET_RECRUITING","2026-04-28",{"date":59,"type":60},"2026-05-04","ACTUAL",{"date":62,"type":41},"2026-04-01",{"date":64,"type":41},"2028-12-31",{"name":5,"class":6}]